| Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid J Xi, Q Chang, CK Chan, ZY Meng, GN Wang, JB Sun, YT Wang, ... AAPS PharmSciTech 10 (1), 172-182, 2009 | 220 | 2009 |
| JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib PG Traves, B Murray, F Campigotto, R Galien, A Meng, JA Di Paolo Annals of the Rheumatic Diseases 80 (7), 865-875, 2021 | 178 | 2021 |
| Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis SM Borgia, J Dearden, EM Yoshida, SD Shafran, A Brown, Z Ben-Ari, ... Journal of hepatology 71 (4), 660-665, 2019 | 129 | 2019 |
| A prospective cohort study comparing early opioid requirement between Chinese from Hong Kong and Caucasian Australians after major abdominal surgery AH Konstantatos, G Imberger, M Angliss, CHK Cheng, AZY Meng, ... British journal of anaesthesia 109 (5), 797-803, 2012 | 37 | 2012 |
| Targeted Genotyping Identifies Susceptibility Locus in Brain-derived Neurotrophic Factor Gene for Chronic Postsurgical Pain (vol 128, pg 587, 2018) Y Tian, X Liu, M Jia, H Yu, P Lichtner, Y Shi, Z Meng, S Kou, IHT Ho, B Jia, ... ANESTHESIOLOGY 128 (5), 1049-1049, 2018 | 34* | 2018 |
| Targeted genotyping identifies susceptibility locus in brain-derived neurotrophic factor gene for chronic postsurgical pain Y Tian, X Liu, M Jia, H Yu, P Lichtner, Y Shi, Z Meng, S Kou, IHT Ho, B Jia, ... Anesthesiology 128 (3), 587-597, 2018 | 34 | 2018 |
| Up-regulation of Cathepsin G in the Development of Chronic Postsurgical PainAn Experimental and Clinical Genetic Study X Liu, Y Tian, Z Meng, Y Chen, IHT Ho, KW Choy, P Lichtner, SH Wong, ... Anesthesiology: The Journal of the American Society of Anesthesiologists 123 …, 2015 | 32 | 2015 |
| Phase 1 First‐in‐Human, Single‐and Multiple‐Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of … P German, Y Xin, JW Chien, W Weng, R Mackman, SA Lewis, A Meng, ... The Journal of Clinical Pharmacology 58 (8), 1025-1034, 2018 | 14 | 2018 |
| Exposure‐Response Relationships for Efficacy and Safety of Filgotinib and its metabolite GS‐829845 in Subjects with Rheumatoid Arthritis Based on Phase 2 and Phase 3 Studies A Meng, K Anderson, C Nelson, L Ni, SM Chuang, F Bellanti, P Chang, ... British Journal of Clinical Pharmacology, 2021 | 5 | 2021 |
| Pharmacokinetics of Once Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 3 to< 6 Years Old R Begley, A Meng, B Massetto, J Shao, J Ling, A Mathias HEPATOLOGY 68, 582A-582A, 2018 | 4 | 2018 |
| THU0067 JAK SELECTIVITY AND THE IMPACT ON CYTOKINE SIGNALING INHIBITION AT CLINICAL RHEUMATOID ARTHRITIS DOSES P Gonzalez-Traves, B Murray, F Campigotto, A Meng, JADI Paolo Annals of the Rheumatic Diseases 79 (Suppl 1), 246-246, 2020 | 3 | 2020 |
| Is Bioequivalence Established Based on the Reference‐Scaled Average Bioequivalence Approach Relevant to Chronic Administration of Phenytoin? Perspectives Based on Population … H Kim, L Fang, J Yu, Z Meng, MN Trame, S Schmidt, LJ Lesko, L Zhao The Journal of Clinical Pharmacology 59 (8), 1061-1069, 2019 | 3 | 2019 |
| POS0224 SELECTIVITY OF CLINICAL JAK INHIBITORS AND THE IMPACT ON NATURAL KILLER (NK) CELL FUNCTIONAL RESPONSES P Gonzalez-Traves, L Simpson, B Murray, A Meng, JA Di Paolo, E Grant, ... Annals of the Rheumatic Diseases 80 (Suppl 1), 331-331, 2021 | 1 | 2021 |
| SAT0149 EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN SUBJECTS WITH RHEUMATOID ARTHRITIS BASED ON PHASE 2 AND PHASE 3 … A Meng, K Anderson, C Nelson, B Kirby, L Ni, SM Chuang, B Kearney, ... Annals of the Rheumatic Diseases 79 (Suppl 1), 1013-1014, 2020 | 1 | 2020 |
| THU0017 IN VITRO MECHANISTIC STUDIES DEMONSTRATE FILGOTINIB ACTIVITY THAT HAS POTENTIAL IMPLICATIONS FOR DIFFERENTIATION AMONG JAK INHIBITORS P Han, A Meng, N Mollova, Y Yu, JADI Paolo Annals of the Rheumatic Diseases 78 (Suppl 2), 276-276, 2019 | 1 | 2019 |
| Population PK/PD Modeling for Evaluation of Filgotinib Efficacy in Subjects with Moderate to Severe Crohn's Disease A Meng, S Sharma, Y Xin, F Namour, A Mathias JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S17-S17, 2017 | 1 | 2017 |
| Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA A Meng, R Humeniuk, JM Jürgensmeier, CH Hsueh, F Matzkies, E Grant, ... Clinical Pharmacology & Therapeutics 111 (2), 416-424, 2022 | | 2022 |
| EVALUATION OF POTENTIAL MECHANISMS UNDERLYING THE SAFETY OBSERVATIONS OF FILGOTINIB IN CLINICAL STUDIES IN RA A Clarke, J Di Paolo, B Downie, A Meng, N Mollova, Y Yu, P Han Gastroenterology 158 (6), S1212-S1212, 2020 | | 2020 |
| Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in rheumatoid arthritis A Clarke, J Di Paolo, B Downie, A Meng, N Mollova, Y Yu, P Han JOURNAL OF CROHNS & COLITIS 14, S409-S409, 2020 | | 2020 |
| Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA J Di Paolo, B Downie, A Meng, N Mollova, Y Yu, P Han ARTHRITIS & RHEUMATOLOGY 71, 2019 | | 2019 |
William K.K. WuThe Chinese University of Hong KongVerified email at cuhk.edu.hk
